another name for bydureon
Implementation. 1  Some medications may need to be taken 1 hr before exenatide. 2  Subcutaneous: Immediate release: Follow directions for New Pen Setup in Information for Patient prior to use of each new pen. 3  Subcutaneous: Extended release: Dilute with diluent and needles included in tray. ☞ Tell patient that Bydureon is provided in a single-dose tray containing one 2-mg vial of drug, one vial connector, one prefilled diluent syringe, and two needles (one provided as a spare). Instruct patient not to substitute needles or any other components in tray. • Be aware that Bydureon is intended for patient self-administration and must be administered immediately after powder is suspended. • Don't coadminister Bydureon and Byetta. Adverse reactions. CNS: dizziness, headache, asthenia, jitteriness. GI: nausea, vomiting, diarrhea, dyspepsia, gastroesophageal reflux disease, acute pancreatitis LILLY (ELI) & COMPANY - Bydureon Reply Submitted To FDA As well as the positive guidance from the SMC on the use of BYETTA, there has recently been a reimbursement approval for BYETTA in Sweden where the Pharmaceutical Benefits Board (LFN) concluded that BYETTA should be reimbursed in the pharmaceutical benefits system for use in people with type 2 diabetes. Bydureon (trade name), Byetta (trade name) Classification Therapeutic: antidiabetics Pharmacologic: incretin mimetic agents. Pregnancy Category: C Indications. Management of type 2 diabetes as an adjunct to diet and exercise. Action. Mimics the action of incretin which promotes endogenous insulin secretion and promotes other mechanisms of glucose-lowering. • concurrent use of insulin (Bydureon use not recommended); concurrent use of prandial insulin (Byetta use not recommended); or concurrent use of other glucose-independent insulin secretagogues (Byetta) • elderly patients. • pregnant or breastfeeding patients. • children (safety and efficacy not established). Patient/Family Teaching. 1  Instruct patient to take exenatide immediate release as directed within 60 min before a meal. Do not take after a meal. If a dose is missed, skip the dose and take the next dose at the prescribed time. Do not take an extra dose or increase the amount of the next dose to make up for missed dose. ➣ Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Adults: 5 mcg (Byetta) injected subcutaneously in thigh, abdomen, or upper arm twice daily within 60 minutes before morning and evening meals. Or, 2 mg (Bydureon) injected subcutaneously once q 7 days (weekly) at any time of day, with or without meals. Dosage adjustment • Concurrent sulfonylurea use (Byetta) Nursing assessment. 1  Observe for signs and symptoms of hypoglycemic reactions (abdominal pain, sweating, hunger, weakness, dizziness, headache, drowsiness, tremor, tachycardia, anxiety, confusion, irritability, jitteriness), especially when combined with oral sulfonylureas.
The another name for bydureon is Byetta.